Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07488676 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary endpoints: details revised at 2 of 8 entriesTrial sites expanded: 17 → 21 locations · Eligibility criteria expanded, about 27 words · Secondary endpoints: details revised at 8 of 32 entriesShow 3 more changesShow less
Trial sites expanded: 17 → 21 locations
Eligibility criteria expanded, about 27 words
Secondary endpoints: details revised at 8 of 32 entries
MinorTrial sites expanded: 14 → 17 locationsv6
MinorStudy sites: 12 to 14v5
MinorTrial sites expanded: 9 → 12 locationsv4
NotableStart date: Mar 20, 2026 to May 4, 2026Study sites: 8 to 9v3Show 1 more changeShow less
Study sites: 8 to 9
NotableRecruitment openedTrial sites expanded: 0 → 8 locations · Start date changed from estimate of Mar 31, 2026 to Mar 20, 2026 · Eligibility criteria expanded, about 35 wordsv2Show 3 more changesShow less
Trial sites expanded: 0 → 8 locations
Start date changed from estimate of Mar 31, 2026 to Mar 20, 2026
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach.
This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion.
In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C.
In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C.
People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.